The DOI matches its Crossref record; 139 of the 139 references it cites were found in a registry or an index.
An Update on the Nitrogen Heterocycle Compositions and Properties of U.S. FDA-Approved Pharmaceuticals (2013–2023)
Abstract
This Perspective is a continuation of our analysis of U.S. FDA-approved small-molecule drugs (1938–2012) containing nitrogen heterocycles. In this study we report drug structure and property analyses of 321 unique new small-molecule drugs approved from January 2013 to December 2023 as well as information about frequency of important heteroatoms such as sulfur and fluorine and key small nitrogen substituents (CN and NO 2 ). The most notable change is an incredible increase in drugs containing at least one nitrogen heterocycle─82%, compared to 59% from preceding decades─as well as a significant increase in the number of nitrogen heterocycles per drug. Pyridine has claimed the #1 high-frequency nitrogen heterocycle occurrence spot from piperidine (#2), with pyrimidine (#5), pyrazole (#6), and morpholine (#9) being the big top 10 climbers. Also notable is high number of fused nitrogen heterocycles, apparently driven largely by newly approved cancer drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019
Newman, D. J., & Cragg, G. M. (2020) · Journal of Natural Products · doi:10.1021/acs.jnatprod.9b01285 · Cited by 7,015
Vitaku, E., Smith, D. T., & Njardarson, J. T. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501100b · Cited by 6,418
Self-citationEscape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success
Lovering, F., Bikker, J., & Humblet, C. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901241e · Cited by 4,495
ChEMBL: a large-scale bioactivity database for drug discovery
Gaulton, A., Bellis, L. J., Bento, A. P., Chambers, J., Davies, M., Hersey, A., Light, Y., McGlinchey, S., Michalovich, D., Al-Lazikani, B., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr777 · Cited by 4,382
Applications of Fluorine in Medicinal Chemistry
Gillis, E. P., Eastman, K. J., Hill, M. D., Donnelly, D. J., & Meanwell, N. A. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00258 · Cited by 3,618
PROTAC targeted protein degraders: the past is prologue
Békés, M., Langley, D. R., & Crews, C. M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00371-6 · Cited by 3,395
Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design
Meanwell, N. A. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01788 · Cited by 2,655
Quantifying the chemical beauty of drugs
Bickerton, G. R., Paolini, G. V., Besnard, J., Muresan, S., & Hopkins, A. L. (2012) · Nature Chemistry · doi:10.1038/nchem.1243 · Cited by 2,242
Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore
Fleming, F. F., Yao, L., Ravikumar, P. C., Funk, L., & Shook, B. C. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100762r · Cited by 1,754
Ilardi, E. A., Vitaku, E., & Njardarson, J. T. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401375q · Cited by 1,604
Self-citationChemistry of MRI Contrast Agents: Current Challenges and New Frontiers
Wahsner, J., Gale, E. M., Rodríguez-Rodríguez, A., & Caravan, P. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00363 · Cited by 1,603
A Graphical Journey of Innovative Organic Architectures That Have Improved Our Lives
McGrath, N. A., Brichacek, M., & Njardarson, J. T. (2010) · Journal of Chemical Education · doi:10.1021/ed1003806 · Cited by 1,188
Self-citationAnalysis of US FDA-Approved Drugs Containing Sulfur Atoms
Scott, K. A., & Njardarson, J. T. (2018) · Topics in Current Chemistry · doi:10.1007/s41061-018-0184-5 · Cited by 1,036
Self-citationKinase drug discovery 20 years after imatinib: progress and future directions
Cohen, P., Cross, D., & Jänne, P. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00195-4 · Cited by 1,024
Eastman, R. T., Roth, J. S., Brimacombe, K. R., Simeonov, A., Shen, M., Patnaik, S., & Hall, M. D. (2020) · ACS Central Science · doi:10.1021/acscentsci.0c00489 · Cited by 953
Applications of Deuterium in Medicinal Chemistry
Pirali, T., Serafini, M., Cargnin, S., & Genazzani, A. A. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01808 · Cited by 855
U.S. FDA Approved Drugs from 2015–June 2020: A Perspective
Bhutani, P., Joshi, G., Raja, N., Bachhav, N., Rajanna, P. K., Bhutani, H., Paul, A. T., & Kumar, R. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01786 · Cited by 815
Pham, T. D. M., Ziora, Z. M., & Blaskovich, M. A. T. (2019) · MedChemComm · doi:10.1039/c9md00120d · Cited by 785
Morin, C. M., Drake, C. L., Harvey, A. G., Krystal, A. D., Manber, R., Riemann, D., & Spiegelhalder, K. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.26 · Cited by 746
Metabolic and Pharmaceutical Aspects of Fluorinated Compounds
Johnson, B. M., Shu, Y.-Z., Zhuo, X., & Meanwell, N. A. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01877 · Cited by 719
Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease
Jonasch, E., Donskov, F., Iliopoulos, O., Rathmell, W. K., Narayan, V. K., Maughan, B. L., Oudard, S., Else, T., Maranchie, J. K., Welsh, S. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103425 · Cited by 714
A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice
Green, E. M., Wakimoto, H., Anderson, R. L., Evanchik, M. J., Gorham, J. M., Harrison, B. C., Henze, M., Kawas, R., Oslob, J. D., Rodriguez, H. M., et al. (2016) · Science · doi:10.1126/science.aad3456 · Cited by 707
Zarrinkar, P. P., Gunawardane, R. N., Cramer, M. D., Gardner, M. F., Brigham, D., Belli, B., Karaman, M. W., Pratz, K. W., Pallares, G., Chao, Q., et al. (2009) · Blood · doi:10.1182/blood-2009-05-222034 · Cited by 634
Nepali, K., Lee, H.-Y., & Liou, J.-P. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00147 · Cited by 629
Deuterium in drug discovery: progress, opportunities and challenges
Di Martino, R. M. C., Maxwell, B. D., & Pirali, T. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00703-8 · Cited by 539
Drilon, A., Ou, S.-H. I., Cho, B. C., Kim, D.-W., Lee, J., Lin, J. J., Zhu, V. W., Ahn, M.-J., Camidge, D. R., Nguyen, J., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0484 · Cited by 504
Furet, P., Guagnano, V., Fairhurst, R. A., Imbach-Weese, P., Bruce, I., Knapp, M., Fritsch, C., Blasco, F., Blanz, J., Aichholz, R., et al. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.05.007 · Cited by 483
Popovici-Muller, J., Lemieux, R. M., Artin, E., Saunders, J. O., Salituro, F. G., Travins, J., Cianchetta, G., Cai, Z., Zhou, D., Cui, D., et al. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00421 · Cited by 442
Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges
Atadja, P. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.02.019 · Cited by 419
Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update
Roskoski, R. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107059 · Cited by 383
Moilanen, A.-M., Riikonen, R., Oksala, R., Ravanti, L., Aho, E., Wohlfahrt, G., Nykänen, P. S., Törmäkangas, O. P., Palvimo, J. J., & Kallio, P. J. (2015) · Scientific Reports · doi:10.1038/srep12007 · Cited by 379
Beyond the Rule of 5: Lessons Learned from AbbVie’s Drugs and Compound Collection: Miniperspective
DeGoey, D. A., Chen, H.-J., Cox, P. B., & Wendt, M. D. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00717 · Cited by 378
Self-citationSmith, B. R., Eastman, C. M., & Njardarson, J. T. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501105n · Cited by 372
Self-citationEnantioselective Total Synthesis of Ecteinascidin 743
Corey, E. J., Gin, D. Y., & Kania, R. S. (1996) · Journal of the American Chemical Society · doi:10.1021/ja962480t · Cited by 352
Recent advances in the total syntheses of oxazole-containing natural products
Yeh, V. S. C. (2004) · Tetrahedron · doi:10.1016/j.tet.2004.10.001 · Cited by 338
Eluxadoline for Irritable Bowel Syndrome with Diarrhea
Lembo, A. J., Lacy, B. E., Zuckerman, M. J., Schey, R., Dove, L. S., Andrae, D. A., Davenport, J. M., McIntyre, G., Lopez, R., Turner, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1505180 · Cited by 334
Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist
Pan, S., Wu, X., Jiang, J., Gao, W., Wan, Y., Cheng, D., Han, D., Liu, J., Englund, N. P., Wang, Y., et al. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml1000307 · Cited by 325
Macrocycles in Drug Discovery─Learning from the Past for the Future
Garcia Jimenez, D., Poongavanam, V., & Kihlberg, J. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00134 · Cited by 321
A Decade of FDA-Approved Drugs (2010–2019): Trends and Future Directions
Brown, D. G., & Wobst, H. J. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01516 · Cited by 320
The histamine H3 receptor: from discovery to clinical trials with pitolisant
Schwartz, J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01286.x · Cited by 318
A Survey of the Structures of US FDA Approved Combination Drugs
Das, P., Delost, M. D., Qureshi, M. H., Smith, D. T., & Njardarson, J. T. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01610 · Cited by 312
Self-citationYoung, R. J., Green, D. V. S., Luscombe, C. N., & Hill, A. P. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.06.001 · Cited by 311
Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions
McGinley, M. P., & Cohen, J. A. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00244-0 · Cited by 310
Tsou, H.-R., Overbeek-Klumpers, E. G., Hallett, W. A., Reich, M. F., Floyd, M. B., Johnson, B. D., Michalak, R. S., Nilakantan, R., Discafani, C., Golas, J., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm040159c · Cited by 301
Menichincheri, M., Ardini, E., Magnaghi, P., Avanzi, N., Banfi, P., Bossi, R., Buffa, L., Canevari, G., Ceriani, L., Colombo, M., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00064 · Cited by 299
Durand-Réville, T. F., Guler, S., Comita-Prevoir, J., Chen, B., Bifulco, N., Huynh, H., Lahiri, S., Shapiro, A. B., McLeod, S. M., Carter, N. M., et al. (2017) · Nature Microbiology · doi:10.1038/nmicrobiol.2017.104 · Cited by 285
Chirality of New Drug Approvals (2013–2022): Trends and Perspectives
McVicker, R. U., & O’Boyle, N. M. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02239 · Cited by 255
Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors
Coleman, K. (2011) · Current Opinion in Microbiology · doi:10.1016/j.mib.2011.07.026 · Cited by 241
Venetoclax: First Global Approval
Deeks, E. D. (2016) · Drugs · doi:10.1007/s40265-016-0596-x · Cited by 236
The Novel Antioxidant Edaravone: From Bench to Bedside
Watanabe, T., Tahara, M., & Todo, S. (2008) · Cardiovascular Therapeutics · doi:10.1111/j.1527-3466.2008.00041.x · Cited by 227
Kenda, B. M., Matagne, A. C., Talaga, P. E., Pasau, P. M., Differding, E., Lallemand, B. I., Frycia, A. M., Moureau, F. G., Klitgaard, H. V., Gillard, M. R., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030913e · Cited by 226
Triazoles in Medicinal Chemistry: Physicochemical Properties, Bioisosterism, and Application
Guan, Q., Xing, S., Wang, L., Zhu, J., Guo, C., Xu, C., Zhao, Q., Wu, Y., Chen, Y., & Sun, H. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00652 · Cited by 216
Phenols in Pharmaceuticals: Analysis of a Recurring Motif
Scott, K. A., Cox, P. B., & Njardarson, J. T. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00223 · Cited by 206
Self-citationFollmann, M., Ackerstaff, J., Redlich, G., Wunder, F., Lang, D., Kern, A., Fey, P., Griebenow, N., Kroh, W., Becker-Pelster, E.-M., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00449 · Cited by 205
Discovery of GBT440, an Orally Bioavailable R-State Stabilizer of Sickle Cell Hemoglobin
Metcalf, B., Chuang, C., Dufu, K., Patel, M. P., Silva-Garcia, A., Johnson, C., Lu, Q., Partridge, J. R., Patskovska, L., Patskovsky, Y., et al. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00491 · Cited by 203
Triclabendazole: new skills to unravel an old(ish) enigma
Fairweather, I. (2005) · Journal of Helminthology · doi:10.1079/joh2005298 · Cited by 199
Nitroimidazoles: Molecular Fireworks That Combat a Broad Spectrum of Infectious Diseases
Ang, C. W., Jarrad, A. M., Cooper, M. A., & Blaskovich, M. A. T. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00143 · Cited by 195
Migalastat: A Review in Fabry Disease
McCafferty, E. H., & Scott, L. J. (2019) · Drugs · doi:10.1007/s40265-019-01090-4 · Cited by 193
Design and optimization of highly-selective fungal CYP51 inhibitors
Hoekstra, W. J., Garvey, E. P., Moore, W. R., Rafferty, S. W., Yates, C. M., & Schotzinger, R. J. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.05.068 · Cited by 192
The NF1 gene revisited - from bench to bedside
Yap, Y.-S., McPherson, J. R., Ong, C.-K., Rozen, S. G., Teh, B.-T., Lee, A. S. G., & Callen, D. F. (2014) · Oncotarget · doi:10.18632/oncotarget.2194 · Cited by 189
Overview of the New Oral Anticoagulants: Opportunities and Challenges
Yeh, C. H., Hogg, K., & Weitz, J. I. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.303397 · Cited by 189
Markham, A. (2021) · Drugs · doi:10.1007/s40265-021-01470-9 · Cited by 188
Lin, C.-W., Sherman, B., Moore, L. A., Laethem, C. L., Lu, D.-W., Pattabiraman, P. P., Rao, P. V., deLong, M. A., & Kopczynski, C. C. (2018) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2017.0023 · Cited by 187
Application and synthesis of thiazole ring in clinically approved drugs
Niu, Z.-X., Wang, Y., Wang, Y.-T., Zhang, S.-N., Li, Y., Chen, X., Wang, S., & Liu, H. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115172 · Cited by 179
DeWitt, S. H., & Maryanoff, B. E. (2018) · Biochemistry · doi:10.1021/acs.biochem.7b00765 · Cited by 177
Target-Based Evaluation of “Drug-Like” Properties and Ligand Efficiencies
Leeson, P. D., Bento, A. P., Gaulton, A., Hersey, A., Manners, E. J., Radoux, C. J., & Leach, A. R. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00416 · Cited by 176
Discovery of BAF312 (Siponimod), a Potent and Selective S1P Receptor Modulator
Pan, S., Gray, N. S., Gao, W., Mi, Y., Fan, Y., Wang, X., Tuntland, T., Che, J., Lefebvre, S., Chen, Y., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml300396r · Cited by 171
Rice, K. D., Aay, N., Anand, N. K., Blazey, C. M., Bowles, O. J., Bussenius, J., Costanzo, S., Curtis, J. K., Defina, S. C., Dubenko, L., et al. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml300049d · Cited by 167
Belgiovine, C., Bello, E., Liguori, M., Craparotta, I., Mannarino, L., Paracchini, L., Beltrame, L., Marchini, S., Galmarini, C. M., Mantovani, A., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.205 · Cited by 165
Nakamura, M., Cho, J.-H., Shin, H., & Jang, I.-S. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.05.007 · Cited by 165
Li, H., Xiao, H., Lin, L., Jou, D., Kumari, V., Lin, J., & Li, C. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401144z · Cited by 161
Caravella, J. A., Lin, J., Diebold, R. B., Campbell, A.-M., Ericsson, A. M., Gustafson, G. R., Wang, Z., Castro, J., Clarke, A., Gotur, D., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01423 · Cited by 161
Sun, Q., Zhou, J., Zhang, Z., Guo, M., Liang, J., Zhou, F., Long, J., Zhang, W., Yin, F., Cai, H., et al. (2014) · Cancer Biology & Therapy · doi:10.4161/15384047.2014.964087 · Cited by 159
Garces, A. E., & Stocks, M. J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01492 · Cited by 152
Ratni, H., Scalco, R., & Stephan, A. H. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00659 · Cited by 144
Amisulpride: A Review of its Use in the Management of Schizophrenia
McKeage, K., & Plosker, G. L. (2004) · CNS Drugs · doi:10.2165/00023210-200418130-00007 · Cited by 138
Privileged Structures in Drug Discovery
Yet, L. (2018) · Wiley eBooks · doi:10.1002/9781118686263 · Cited by 135
Dhillon, S. (2021) · Drugs · doi:10.1007/s40265-020-01464-z · Cited by 131
Hoegenauer, K., Soldermann, N., Zécri, F. J., Strang, R. S., Graveleau, N., Wolf, R. M., Cooke, N. G., Smith, A. B., Hollingworth, G. J., Blanz, J., et al. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00293 · Cited by 129
Review of deutetrabenazine: a novel treatment for chorea associated with Huntington's disease
Dean, M. N., & Sung, V. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s138828 · Cited by 124
Vortioxetine: a novel antidepressant for the treatment of major depressive disorder
Gonda, X., Sharma, S. R., & Tarazi, F. I. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1546691 · Cited by 123
Drug Strategies Targeting CYP51 in Neglected Tropical Diseases
Choi, J. Y., Podust, L. M., & Roush, W. R. (2014) · Chemical Reviews · doi:10.1021/cr5003134 · Cited by 117
Lefamulin: Review of a Promising Novel Pleuromutilin Antibiotic
Veve, M. P., & Wagner, J. L. (2018) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2166 · Cited by 117
Molybdenum cofactor and human disease
Schwarz, G. (2016) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2016.03.016 · Cited by 115
Blair, H. A. (2023) · Drugs · doi:10.1007/s40265-023-01928-y · Cited by 112
Edmondson, S. D., Zhu, C. G., Kar, N. F., Salvo, J. D., Nagabukuro, H., Sacre-Salem, B., Dingley, K. H., Berger, R., Goble, S. D., Morriello, G. J., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01372 · Cited by 108
Ramesh, D., Vijayakumar, B. G., & Kannan, T. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112801 · Cited by 106
Morgan, K. A., Rudd, S. E., Noor, A., & Donnelly, P. S. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00456 · Cited by 105
Zhong, M., Gadek, T. R., Bui, M., Wang, S., Burnier, J. P., Barr, K. J., Hanan, E. J., Oslob, J. D., Yu, C. H., Zhu, J., et al. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml2002482 · Cited by 102
Baillache, D. J., & Unciti‐Broceta, A. (2020) · RSC Medicinal Chemistry · doi:10.1039/d0md00227e · Cited by 101
Omaveloxolone: a groundbreaking milestone as the first FDA-approved drug for Friedreich ataxia
Pilotto, F., Chellapandi, D. M., & Puccio, H. M. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.12.002 · Cited by 94
Yoshida, Y., Naoe, Y., Terauchi, T., Ozaki, F., Doko, T., Takemura, A., Tanaka, T., Sorimachi, K., Beuckmann, C. T., Suzuki, M., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00217 · Cited by 91
Recent Progress in the Discovery of Antifungal Agents Targeting the Cell Wall
Liu, W., Yuan, L., & Wang, S. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00748 · Cited by 87
Three US Food and Drug Administration–approved therapies for chronic GVHD
Zeiser, R., & Lee, S. J. (2022) · Blood · doi:10.1182/blood.2021014448 · Cited by 83
Discovery of Pemigatinib: A Potent and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor
Wu, L., Zhang, C., He, C., Qian, D., Lü, L., Sun, Y., Xu, M., Zhuo, J., Liu, P. C. C., Klabe, R. M., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00713 · Cited by 82
Dash, R. P., Babu, R. J., & Srinivas, N. R. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0655-4 · Cited by 79
Gepants for Acute and Preventive Migraine Treatment: A Narrative Review
Rissardo, J. P., & Caprara, A. L. F. (2022) · Brain Sciences · doi:10.3390/brainsci12121612 · Cited by 79
Maccari, R., & Ottanà, R. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00867 · Cited by 78
Buzard, D. J., Kim, S. H., Lopez, L., Kawasaki, A. M., Zhu, X., Moody, J., Thoresen, L. H., Calderon, I., Ullman, B. R., Han, S., et al. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500389m · Cited by 76
Mainolfi, N., Ehara, T., Karki, R. G., Anderson, K., Sweeney, A. M., Liao, S.-M., Argikar, U. A., Jendza, K. C., Zhang, C., Powers, J. J., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01870 · Cited by 74
A Review on Dry Eye Disease Treatment: Recent Progress, Diagnostics, and Future Perspectives
Mondal, H., Kim, H., Mohanto, N., & Jee, J. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030990 · Cited by 74
Veselinović, T., Paulzen, M., & Gründer, G. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2013.853448 · Cited by 69
Zheng, J., Zhang, X., & Zhen, X. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00313 · Cited by 68
Advances in Epilepsy: Mechanisms, Clinical Trials, and Drug Therapies
Hu, T., Zhang, J., Wang, J., Sha, L., Xia, Y., Ortyl, T. C., Tian, X., & Chen, L. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01975 · Cited by 59
Hill, D. R., Huters, A. D., Towne, T. B., Reddy, R. E., Fogle, J. L., Voight, E. A., & Kym, P. R. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00479 · Cited by 57
Agents for the Treatment of Gout: Current Advances and Future Perspectives
Zeng, X., Liu, Y., Fan, Y., Wu, D., Meng, Y., & Qin, M. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01710 · Cited by 54
Management of Thrombocytopenia in Chronic Liver Disease: Focus on Pharmacotherapeutic Strategies
Maan, R., de Knegt, R. J., & Veldt, B. J. (2015) · Drugs · doi:10.1007/s40265-015-0480-0 · Cited by 53
Meredith, E. L., Ksander, G. M., Monovich, L. G., Papillon, J. P. N., Liu, Q., Miranda, K., Morris, P., Rao, C., Burgis, R., Capparelli, M. P., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400324c · Cited by 52
Lead-like Drugs: A Perspective
Raymer, B. K., & Bhattacharya, S. K. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00407 · Cited by 52
Tafenoquine: A Step toward Malaria Elimination
Lu, K., & Derbyshire, E. R. (2020) · Biochemistry · doi:10.1021/acs.biochem.9b01105 · Cited by 51
A review of the pharmacology and clinical profile of lumateperone for the treatment of schizophrenia
Snyder, G. L., Vanover, K. E., Davis, R. E., Li, P., Fienberg, A. A., & Mates, S. L. (2020) · Advances in pharmacology · doi:10.1016/bs.apha.2020.09.001 · Cited by 41
Guo, Y., Zhang, J., Sun, J., & Gao, H. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116185 · Cited by 41
Meanwell, N. A. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00915 · Cited by 40
Development of a Commercial Process for Deucravacitinib, a Deuterated API for TYK2 Inhibition
Treitler, D. S., Soumeillant, M. C., Simmons, E. M., Lin, D., Inankur, B., Rogers, A. J., Dummeldinger, M., Kolotuchin, S. V., Chan, C., Li, J., et al. (2022) · Organic Process Research & Development · doi:10.1021/acs.oprd.1c00468 · Cited by 40
Guerra, L., Favia, M., Gioia, S. D., Laselva, O., Bisogno, A., Casavola, V., Colombo, C., & Conese, M. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1750592 · Cited by 38
Advances in Development of Selective Antitumor Inhibitors That Target PARP-1
Liu, F., Chen, J., Li, X., Liu, R., Zhang, Y., Gao, C., & Shi, D. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00865 · Cited by 38
A Comprehensive Review of Pacritinib in Myelofibrosis
Verstovšek, S., & Komrokji, R. S. (2015) · Future Oncology · doi:10.2217/fon.15.200 · Cited by 37
Encorafenib and binimetinib for the treatment of BRAF V600E/K-mutated melanoma
Rose, A. A. N. (2019) · Drugs of today · doi:10.1358/dot.2019.55.4.2958476 · Cited by 36
Zhang, L., Griffin, D. J., Beaver, M. G., Blue, L. E., Borths, C. J., Brown, D. B., Caille, S., Chen, Y., Cherney, A. H., Cochran, B. M., et al. (2022) · Organic Process Research & Development · doi:10.1021/acs.oprd.2c00249 · Cited by 35
Avapritinib for Systemic Mastocytosis
Bose, P., & Verstovšek, S. (2021) · Expert Review of Hematology · doi:10.1080/17474086.2021.1959315 · Cited by 34
Abbott Physicochemical Tiering (APT)—A unified approach to HTS triage
Cox, P. B., Gregg, R. J., & Vasudevan, A. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.05.047 · Cited by 31
Self-citationConnor, C. G., DeForest, J. C., Dietrich, P., Do, N. M., Doyle, K. M., Eisenbeis, S. A., Greenberg, E., Griffin, S. H., Jones, B. P., Jones, K. N., et al. (2020) · Organic Process Research & Development · doi:10.1021/acs.oprd.0c00366 · Cited by 29
Viloxazine: Pediatric First Approval
Lamb, Y. N. (2021) · Pediatric Drugs · doi:10.1007/s40272-021-00453-3 · Cited by 29
Ben-Barouch, S., & Kuruvilla, J. G. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1706087 · Cited by 27
Midostaurin treatment inFLT3-mutated acute myeloid leukemia and systemic mastocytosis
Käyser, S., Levis, M. J., & Schlenk, R. F. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1387051 · Cited by 26
Uslaner, J. M., Herring, W. J., & Coleman, P. J. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00110 · Cited by 23
Jacobs, J. W., Leadbetter, M. R., Bell, N., Koo-McCoy, S., Carreras, C. W., He, L., Kohler, J. N., Kozuka, K., Labonté, E. D., Navre, M., et al. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00037 · Cited by 23
Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations
Wang, Z., Li, Q., Cai, J., Wu, J., Wang, J., Zhang, M., Wang, Q.-X., Tong, Z., Yang, J., Wei, T., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02319 · Cited by 21
Kang, C. (2021) · Drugs · doi:10.1007/s40265-021-01520-2 · Cited by 19
El‐Mansy, M. F., Reidl, C. T., Rahaman, M., Özdinler, P. H., & Silverman, R. B. (2023) · Medicinal Research Reviews · doi:10.1002/med.21974 · Cited by 18
Martino, S. D., Petri, G. L., & Rosa, M. D. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01971 · Cited by 17
Kargbo, R. B. (2023) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.3c00388 · Cited by 16
Davis, D. D., Ohana, Z., & Pham, H. (2023) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552231216886 · Cited by 15
Weinreb, R. N., Realini, T., & Varma, R. (2016) · touchREVIEWS in Ophthalmology · doi:10.17925/usor.2016.09.02.80 · Cited by 12
Review of Synthetic Approaches toward the Synthesis of Cariprazine, an Antipsychotic Drug
Bhosle, S. D., Itage, S. V., Gangapuram, B., Gyanchander, E., Bhosale, R. S., & Yadav, J. S. (2022) · Organic Process Research & Development · doi:10.1021/acs.oprd.1c00488 · Cited by 12
Terlipressin for hepatorenal syndrome: opportunities and challenges
Singal, A. K., & Jalan, R. (2023) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(22)00377-6 · Cited by 9
Aggarwal, A., Gopalakrishna, G., & Lauriello, J. (2016) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.agga.040316 · Cited by 8
Migraine and Its Treatment from the Medicinal Chemistry Perspective
Pehlivanlar, E., Carradori, S., & Şimşek, R. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00370 · Cited by 6
Metadata
- Authors
- Marshall, C. M., Federice, J. G., Bell, C. N., Cox, P. B., & Njardarson, J. T.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2024-07-12
- Volume
- 67
- Issue
- 14
- Pages
- 11622-11655
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W4400581728
- Cited by
- 1,064
- References
- 139
- FWCI
- 208.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.